Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
331
datasets available to search
ShareScore release 0.9.0
Dataset results
331 results for “omega-3 fatty acids”
FIGURE 4 in Effect of dietary omega-3 polyunsaturated fatty acids supplementation of Astyanax lacustris males on semen quality
FIGURE 4 | Results obtained for A. Head lateral displacement amplitude (ALH, µm) and B. Crossbeat frequency (BCF, Hz), after feeding with the inclusion of PUFAs-ô3 in the diet of Astyanax lacustris for a period of 105 days. In-0 – diet without inclusion of PUFAs-ô3; In-3 – feed with inclusion of 3% PUFAs-ô3; In-6 – feed with inclusion of 6% of PUFAs-ô3; In-9 – feed with inclusion of 9% PUFAs-ô3. Different lowercase letters indicate statistical difference between treatments for ALH and BCF (Kruskal-Wallis, p<0.05).
FIGURE 3 in Effect of dietary omega-3 polyunsaturated fatty acids supplementation of Astyanax lacustris males on semen quality
FIGURE 3 | Results obtained for A. Linearity (LIN, %), B. Straightness coefficient (STR, %) and C. Mean oscillation of the spatial trajectory (WOB, %), after feeding with the inclusion of PUFAs-ô3 in the diet of Astyanax lacustris for a period of 105 days. In-0 – diet without inclusion of PUFAs-ô3; In-3 – feed with inclusion of 3% PUFAs-ô3; In-6 – feed with inclusion of 6% of PUFAs-ô3; In-9 – feed with inclusion of 9% PUFAs-ô3. Different lowercase letters indicate statistical difference between treatments for LIN, STR and WOB (Kruskal-Wallis, p<0.05).
FIGURE 2 in Effect of dietary omega-3 polyunsaturated fatty acids supplementation of Astyanax lacustris males on semen quality
FIGURE 2 | Results obtained for A. Percentage of fast (SptzRápido), medium (SptzMedium) and slow (SptzSlow), B. Curvilinear velocity (VCL, µm/s), C. Linear velocity (VSL, µm/ s), D. Mean velocity (VAP, µm/s%) after feeding with the inclusion of PUFAs-ô3 in the diet of Astyanax lacustris for a period of 105 days. In-0 – diet without inclusion of PUFAs-ô3; In-3 – feed with inclusion of 3% PUFAs-ô3; In-6 – feed with inclusion of 6% of PUFAs-ô3; In-9 – feed with inclusion of 9% PUFAs-ô3. Different capital letters indicate statistical difference between treatments for SptzFast. Different lowercase letters indicate statistical difference between treatments for SptzMedium, SptzSlow percentage, VCL, VSL and VAP (Kruskal-Wallis, p<0.05).
FIGURE 1 in Effect of dietary omega-3 polyunsaturated fatty acids supplementation of Astyanax lacustris males on semen quality
FIGURE 1 | Results obtained for total (MOT, %) and progressive (PRG, %) sperm motility after feeding with the inclusion of PUFAs-ô3 in the diet of Astyanax lacustris for a period of 105 days. In-0 – diet without inclusion of PUFAs-ô3; In-3 – feed with inclusion of 3% PUFAs-ô3; In-6 – feed with inclusion of 6% of PUFAs-ô3; In-9 – feed with inclusion of 9% PUFAs-ô3. Different capital letters indicate statistical difference between treatments for MOT. Different lowercase letters indicate statistical difference between treatments for PRG (Kruskal-Wallis, p<0.05).
Specified Drug-use Survey of the Granular Capsule Formulation of Omega-3 Fatty Acid Ethyl Esters: OCEAN3
ClinicalTrials.gov study NCT02285166. IPD Sharing: YES. Countries: 1. Publications: 1.
Data from: Biosynthesis of long-chain omega-3 fatty acids in a generalist seabird
Open the record for dataset details and reuse information.
Data from: Lipidome modulation by dietary omega-3 polyunsaturated fatty acid supplementation or selective soluble epoxide hydrolase inhibition suppresses rough LPS-accelerated glomerulonephritis in lupus-prone mice
<p>Lipopolysaccharide (LPS)-accelerated autoimmune glomerulonephritis (GN) in lupus-prone NZBWF1 mice is a preclinical model that is potentially applicable for investigating lipidome-modulating interventions. LPS can be expressed as one of two chemotypes: smooth LPS (S-LPS) and rough LPS (R-LPS) which is devoid of O-antigen polysaccharide sidechain. Since these chemotypes differentially affect TLR4-mediated immune cell responses, these differences may influence GN induction. Therefore, we initially compared the effects of subchronic i.p. injection for 5 wk with 1) <em>Salmonella</em> S-LPS, 2) <em>Salmonella</em> R-LPS, or 3) saline vehicle (VEH) (Study 1) in female NZBWF1 mice. R-LPS induced robust elevations in blood urea nitrogen, proteinuria, and hematuria that were not evident in VEH- or S-LPS-treated mice. Histopathologic examination of R-LPS-treated mice one week after final injection further revealed more robust hypertrophy, hyperplasia, thickened membranes, lymphocytic accumulation containing B and T cells, and glomerular IgG deposition consistent with GN but not in VEH- or S-LPS-treated groups. R-LPS but not S-LPS induced spleen enlargement with lymphoid hyperplasia as well as modest inflammatory cell recruitment in the liver. We next employed our optimized R-LPS model to discern the impact of two lipidome-modulating interventions, omega-3 polyunsaturated fatty acid (PUFA) supplementation and soluble epoxide hydrolase (sEH) inhibition, on GN (Study 2). Specifically, the effects of consuming the omega-3 PUFA docosahexaenoic acid (DHA) (10 g/kg diet) and/or the sEH inhibitor TPPU (22.5 mg/kg diet) on R-LPS triggering were compared. Resultant blood fatty acid profiles and epoxy fatty acid concentrations reflected the anticipated DHA- and TPPU-mediated lipidome changes. The relative rank order of R-LPS-induced GN severity among groups fed experimental diets based on proteinuria, hematuria, histopathologic scoring, and glomerular IgG deposition was: VEH/CON < R-LPS/DHA ≈ R-LPS/TPPU <<< R-LPS/ TPPU+DHA ≈ R-LPS/CON. These interventions had modest to negligible effects on R-LPS-induced splenomegaly, plasma antibody responses, liver inflammation, and inflammation-associated kidney gene expression. Collectively, our results show for the first time that absence of O-antigenic polysaccharide in R-LPS is critical to accelerated GN in lupus-prone mice. Furthermore, intervention by lipidome modulation through DHA feeding or sEH inhibition suppressed R-LPS-induced GN; however, these ameliorative effects were greatly diminished upon combining the treatments.</p>
Evolutionary Mismatch and depression: the correlation between omega-3 fatty acid intake from fish in diet and the prevalence of depression among university students
<p>This compressed file contain the data used for the Bachelor project "Evolutionary Mismatch and depression: the correlation between omega-3 fatty acid intake from fish in diet and the prevalence of depression among university students" by Ziyao Zhang from the University of Amsterdam.</p>
Obesity and Asthma: Nutrigenetic Response to Omega-3 Fatty Acids
ClinicalTrials.gov study NCT01027143. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach
ClinicalTrials.gov study NCT02553915. IPD Sharing: NO. Countries: 1. Publications: 4.
Efficacy Study Regarding the Beneficial Effects of Omega-3 Fatty Acids on Cardiometabolic Health
ClinicalTrials.gov study NCT02042274. IPD Sharing: NO. Countries: 1. Publications: 1.
Dietary Essential Fatty Acid Regulation of Omega-3 HUFA Metabolism; Satiety and Body Composition
ClinicalTrials.gov study NCT01251887. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Omega-3 Fatty Acids for Autism Treatment
ClinicalTrials.gov study NCT00786799. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Omega-3 Fatty Acids and Insulin Sensitivity
ClinicalTrials.gov study NCT01686568. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients
ClinicalTrials.gov study NCT00346697. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Omega-3 Fatty Acids, the Omega-3 Index, and Atherosclerosis
ClinicalTrials.gov study NCT00886704. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Lycopene or Omega-3 Fatty Acid Nutritional Supplements in Treating Patients With Stage I or Stage II Prostate Cancer
ClinicalTrials.gov study NCT00402285. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Impact of Omega-3 Fatty Acid Oral Therapy on Healing of Chronic Venous Leg Ulcers in Older Adults
ClinicalTrials.gov study NCT03576989. IPD Sharing: NO. Countries: 1. Publications: 1.
Omega-3 Fatty Acids For Treatment Of Young Children With Autism (OMG)
ClinicalTrials.gov study NCT01248728. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
ClinicalTrials.gov study NCT00167310. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.